EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization

Lv Guangzhao, Wang Xin, Wu Miaoqing, Ma Wenjuan, Liu Ranyi, Pan Zhizhong, Zhang Rongxin, Chen Gong

Cancer Immunology, Immunotherapy · 03.01.2025 · 74 (2)

DOI: 10.1007/s00262-024-03925-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 03.01.2025. Verfasst von Lv Guangzhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Indoleamine-Pyrrole 2,3,-Dioxygenase, Macrophages, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Open research funds from the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Basic and Applied Basic Research Foundation of Guangdong Province, Chinese Society of Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microsatellite stable (MSS) colorectal cancer (CRC) is a subtype of CRC that generally exhibits resistance to immunotherapy, particularly immune checkpoint inhibitors such as PD-1 blockade. This study investigates the effects and underlying mechanisms of combining PD-1 blockade with IDO1 inhibition in MSS CRC. Bioinformatics analyses of TCGA-COAD and TCGA-READ cohorts revealed significantly elevated IDO1 expression in CRC tumors, correlating with tumor mutation burden across TCGA datasets. In vivo experiments demonstrated that the combination of IDO1 inhibition and PD-1 blockade significantly reduced tumor growth and increased immune cell infiltration, particularly pro-inflammatory macrophages and CD8+ T cells. IDO1 knockdown in CRC cell lines impaired tolerance to interferon-γ and increased apoptosis in vitro, which were rescued by the application of kynurenine, the end product of IDO1. IDO1 knockdown in MSS CRC enhanced the effectiveness of PD-1 blockade therapy in vivo. IDO1 knockdown cancer cells promoted pro-inflammatory macrophage polarization and enhanced phagocytic activity in vitro, associated with the upregulation of JAK2-STAT3-IL6 signaling pathway. These findings highlight the role of IDO1 in modulating the tumor immune microenvironment in MSS CRC and suggest that combining PD-1 blockade with IDO1 inhibition could enhance therapeutic efficacy by promoting macrophage pro-inflammatory polarization and infiltration through the JAK2-STAT3-IL6 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsIndoleamine-Pyrrole 2,3,-DioxygenaseMacrophagesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansAnimalsMiceTumor MicroenvironmentPhenotypeXenograft Model Antitumor AssaysCell Line, TumorMicrosatellite InstabilityFemaleSignal TransductionMicrosatellite Repeats

Stichwörter der Autor:innen

IDO1ImmunotherapyMacrophage polarizationMicrosatellite stable colorectal cancerPD-1 blockade

Substanzen

Indoleamine-Pyrrole 2,3,-DioxygenaseIDO1 protein, humanImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Radiotherapy, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
  • Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Guangzhou, Guangzhou, Guangdong, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. panzhzh@sysucc.org.cn.

Förderung

  • Open research funds from the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Chinese Society of Clinical Oncology
  • Sun Yat-sen University Basic Research Fund

Zitieren

APA

Guangzhao, L., Xin, W., Miaoqing, W., Wenjuan, M., Ranyi, L., Zhizhong, P., Rongxin, Z., & Gong, C. (2025). IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization. Cancer Immunology, Immunotherapy, 74(2). https://doi.org/10.1007/s00262-024-03925-w

Vancouver

Guangzhao L, Xin W, Miaoqing W, Wenjuan M, Ranyi L, Zhizhong P, et al. IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization. Cancer Immunology, Immunotherapy. 2025;74(2). doi:10.1007/s00262-024-03925-w

BibTeX
@article{Guangzhao2025,
  author = {Guangzhao, Lv and Xin, Wang and Miaoqing, Wu and Wenjuan, Ma and Ranyi, Liu and Zhizhong, Pan and Rongxin, Zhang and Gong, Chen},
  title = {IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {2},
  doi = {10.1007/s00262-024-03925-w}
}
Kostenlos starten →